What’s the current market cap for Nanobiotix stock?

Nanobiotix (NBTX) has a market cap of $1.8bn as of June 08, 2026.

What is the P/E ratio for Nanobiotix stock?

The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of June 08, 2026.

Does Nanobiotix stock pay dividends?

No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of June 08, 2026.

When is the next Nanobiotix dividend payment date?

Nanobiotix (NBTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Nanobiotix?

Nanobiotix (NBTX) has a beta rating of 0.58. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Nanobiotix stock | $NBTX Share Price

13:30

15:10

16:45

18:25

20:00

About Nanobiotix

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Ticker

$NBTX

Sector

Health

Primary listing

NASDAQ

Employees

100

Headquarters

Paris, France

Website

www.nanobiotix.com

Nanobiotix Metrics

BasicAdvanced

$1.8bn

-$0.58

0.58

What the Analysts think about Nanobiotix

Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.

Bulls say / Bears say

Early results from the Phase 2 CONVERGE study in stage III inoperable NSCLC showed an overall response rate of 85.7% and a complete response rate of 57.1%, far surpassing standard-of-care complete response rates, which are below 5%.

The FDA approved a protocol amendment removing the interim analysis for the Phase 3 NANORAY-312 head and neck cancer trial, which could speed up data readout and regulatory milestones.

Nanobiotix secured up to $71 million in non-dilutive royalty financing from HealthCare Royalty, extending its cash runway to early 2028 to support late-stage development.

Nanobiotix reported a net loss of €24.0 million for the year ended 31 December 2025, highlighting its continued unprofitability and ongoing cash burn prior to expected product launches.

The Phase 2 CONVERGE NSCLC results are based on just seven patients, which limits statistical reliability and means larger confirmatory trials are necessary to validate the early efficacy signal.

Milestone payments under the Janssen license agreement depend on development and regulatory events controlled by Johnson & Johnson, introducing timing risk and uncertainty for future cash inflows.

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

Nanobiotix Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Nanobiotix Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NBTX

Capital at risk

Market closedADR

Upcoming events

No upcoming events